Automate Your Wheel Strategy on ABT
With Tiblio's Option Bot, you can configure your own wheel strategy including ABT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABT
- Rev/Share 25.3738
- Book/Share 29.344
- PB 3.7378
- Debt/Equity 0.254
- CurrentRatio 1.7034
- ROIC 0.0874
- MktCap 189744840616.0
- FreeCF/Share 3.9594
- PFCF 27.4317
- PE 29.1934
- Debt/Assets 0.1537
- DivYield 0.022
- ROE 0.1318
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ABT | The Benchmark Company | -- | Buy | -- | $145 | Oct. 10, 2025 |
| Upgrade | ABT | Jefferies | Hold | Buy | -- | $145 | July 18, 2025 |
| Initiation | ABT | Leerink Partners | -- | Market Perform | -- | $143 | June 16, 2025 |
| Initiation | ABT | Oppenheimer | -- | Outperform | -- | $130 | Oct. 8, 2024 |
| Initiation | ABT | Piper Sandler | -- | Overweight | -- | $131 | Sept. 19, 2024 |
News
Abbott recalls glucose sensors after seven deaths linked to faulty readings
Published: February 04, 2026 by: Reuters
Sentiment: Negative
Abbott has recalled certain glucose monitoring sensors after reports linked the devices to seven deaths and 860 serious injuries, the U.S. health regulator said on Wednesday.
Read More
NVST or ABT: Which Is the Better Value Stock Right Now?
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Abbott: Long-Term Investment Opportunity For Dividend Growth Investors
Published: February 02, 2026 by: Seeking Alpha
Sentiment: Positive
In reality, Abbott Laboratories is actually a Dividend Aristocrat – a vaunted status reserved for companies that have increased dividends for at least 25 consecutive years. ABT grew its revenue from $20.8 billion in FY 2016 to $44.3 billion in FY 2025. That's a compound annual growth rate of 8.8%. Abbott Laboratories has a great financial position. The long-term debt/equity ratio is 0.3, while the interest coverage ratio is 17.
Read More
10 Highest Rated Dividend Kings For Generations Of Income
Published: January 29, 2026 by: Seeking Alpha
Sentiment: Positive
My top 10 Dividend Kings list prioritizes reliability, dividend safety, and attractive valuation for long-term, generational income. Selection criteria include payout ratios under 70%, strong dividend safety/growth grades, and favorable Quant, SA, and Wall Street ratings. ABM Industries leads with a low 31% payout ratio, 2.5% yield, B- safety/growth, and an A- valuation grade despite a Hold Quant rating.
Read More
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Abbott (ABT) is a Top-Ranked Value Stock: Should You Buy?
Published: January 23, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Is The Fall In Abbott Stock Justified?
Published: January 23, 2026 by: Forbes
Sentiment: Neutral
Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, aligning with expectations, while the total annual adjusted EPS reached $5.15, indicating a 10% growth.
Read More
Abbott Laboratories Raised Prices, Prompting Sales Slump
Published: January 22, 2026 by: WSJ
Sentiment: Negative
The medical-products maker's shares tumbled after its quarterly profit and sales underwhelmed investors.
Read More
Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript
Published: January 22, 2026 by: Seeking Alpha
Sentiment: Neutral
Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript
Read More
Jobless Claims Come in Slightly Higher
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Negative
Jobless Claims Come in Slightly Higher.
Read More
Crude Oil Down 2%; Abbott Shares Fall Following Q4 Results
Published: January 22, 2026 by: Benzinga
Sentiment: Negative
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Thursday.
Read More
Jobless Claims Stay Low at +200K, Q3 GDP Up to +4.4%
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive
Weekly Jobless Claims continue to portray a labor market cruising along at a healthy low rate of unemployment claims.
Read More
Abbott's Q4 Earnings Meet Estimates, Revenues Miss, Stock Falls
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Negative
ABT's Q4 earnings meet estimates but revenues miss, sending shares down as strong device growth is offset by weaker nutrition and diagnostics sales.
Read More
Abbott (ABT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Abbott (ABT) Matches Q4 Earnings Estimates
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) came out with quarterly earnings of $1.5 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $1.34 per share a year ago.
Read More
Wall Street Analysts Think Abbott (ABT) Is a Good Investment: Is It?
Published: January 21, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
2 Healthcare Names That Could Get a Big Boost From Earnings
Published: January 20, 2026 by: MarketBeat
Sentiment: Positive
Active traders expect companies in the healthcare sector to experience significant share price spikes tied to milestones in the development of new therapies and medical products. The volatility in some corners of the sector makes it a high-risk, but high-reward, opportunity.
Read More
Will Robust Adult Nutrition Business Performance Fuel ABT's Q4 Earnings?
Published: January 19, 2026 by: Zacks Investment Research
Sentiment: Positive
ABT heads into Q4 earnings with adult nutrition in focus, as Ensure and Glucerna launches are expected to support modest segment growth.
Read More
Exact Sciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS
Published: January 16, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK and NEW ORLEANS, Jan. 16, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Read More
Insights Into Abbott (ABT) Q4: Wall Street Projections for Key Metrics
Published: January 16, 2026 by: Zacks Investment Research
Sentiment: Positive
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Abbott (ABT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Read More
Dividend King Abbott Shows Why 52 Consecutive Increases Weren't Luck With Strong Cash Flow Coverage
Published: January 15, 2026 by: 24/7 Wall Street
Sentiment: Positive
Abbott Laboratories (NYSE: ABT) doesn't just pay dividends.
Read More
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
PBH or ABT: Which Is the Better Value Stock Right Now?
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Abbott (ABT). But which of these two stocks is more attractive to value investors?
Read More
Abbott: Not Cheap, But Built To Compound In Uncertain Markets
Published: January 07, 2026 by: Seeking Alpha
Sentiment: Neutral
Abbott Laboratories is a defensive, high-quality compounder with a premium valuation justified by recurring cash flow and strong medical device platforms. Medical Devices, especially Diabetes Care (Libre), are driving over 12% segment growth, with Diabetes Care revenues surpassing $2B and growing 17%. ABT reaffirmed 2025 organic growth guidance of 7.5%–8% and EPS of $5.12–$5.18, with consistent, low-volatility earnings growth expected through 2027.
Read More
PBH vs. ABT: Which Stock Is the Better Value Option?
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Products sector might want to consider either Prestige Consumer Healthcare (PBH) or Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions
Published: January 05, 2026 by: PRNewsWire
Sentiment: Neutral
Traditional food logging apps offer feedback after the fact—Libre Assist1 offers help in-the-moment to inform mealtime decisions before every bite Libre Assist1 leverages AI to predict how food choices affect glucose levels,2 provides personalized meal guidance,3 and confirms glucose impact using data from Abbott's world-leading FreeStyle Libre continuous glucose monitoring (CGM) technology4 Abbott is launching Libre Assist, available at no additional cost within the Libre app,5 during CES® 2026 ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), a leading healthcare company, today unveiled Libre Assist,1 a groundbreaking feature within the Libre app5 designed to help the millions …
Read More
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
Published: December 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Best Dividend Aristocrats For January 2026
Published: December 31, 2025 by: Seeking Alpha
Sentiment: Positive
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%), and CHRW (+61.22%) delivered strong double-digit returns. Dividend growth for the Aristocrats slowed to 5.52% in 2025, down from 5.78% in 2024, with 68 of 69 raising payouts.
Read More
Abbott Stock May Benefit Following Volt PFA's FDA Approval
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
ABT wins FDA approval for its Volt PFA System for AFib, paving the way for U.S. launches and EU expansion after earlier CE Mark clearance.
Read More
Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation
Published: December 22, 2025 by: PRNewsWire
Sentiment: Neutral
Abbott's Volt™ PFA System, the latest generation of cardiac ablation technology, is designed for people battling heart rhythm disorders such as atrial fibrillation (AFib) Pulsed field ablation – or PFA – is a minimally invasive procedure that uses high-energy electrical pulses in targeted areas of the heart to treat irregular heart rhythms Abbott's Volt PFA System is an all-in-one product that is clinically proven to simplify the treatment of AFib that is gentler on the heart, has shorter procedure times and supports better recovery and long-term results ABBOTT PARK, Ill., Dec. 22, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced …
Read More
About Abbott Laboratories (ABT)
- IPO Date 1980-03-17
- Website https://www.abbott.com
- Industry Medical - Devices
- CEO Robert Ford
- Employees 114000